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Available online 18 February 2016Background: Exercise-Induced Muscle Damage (EIMD) and delayed onset muscle soreness (DOMS) impact subse-
quent training sessions and activities of daily living (ADL) even in active individuals. In sedentary or diseased indi-
viduals, EIMD and DOMS may be even more pronounced and present even in the absence of structured exercise.
Methods: The purpose of this study was to determine the effects of oral curcumin supplementation (Longvida®
400 mg/days) on muscle & ADL soreness, creatine kinase (CK), and inﬂammatory cytokines (TNF-α, IL-6, IL-8,
IL-10) following EMID (eccentric-only dual-leg press exercise). Subjects (N=28)were randomly assigned to either
curcumin (400mg/day) or placebo (riceﬂour) and supplemented 2days before to 4 days after EMID. Blood samples
were collected prior to (PRE), and 1, 2, 3, and 4 days after EIMD to measure CK and inﬂammatory cytokines. Data
were analyzed by ANOVA with P b 0.05.
Results: Curcumin supplementation resulted in signiﬁcantly smaller increases in CK (−48%), TNF-α (−25%),
and IL-8 (−21%) following EIMD compared to placebo. We observed no signiﬁcant differences in IL-6, IL-10, or
quadriceps muscle soreness between conditions for this sample size.
Conclusions: Collectively, the ﬁndings demonstrated that consumption of curcumin reduced biological inﬂamma-
tion, but not quadricepsmuscle soreness, during recovery after EIMD. The observed improvements in biological in-
ﬂammationmay translate to faster recovery and improved functional capacity during subsequent exercise sessions.
General signiﬁcance: These ﬁndings support the use of oral curcumin supplementation to reduce the symptoms of
EIMD. The next logical step is to evaluate further the efﬁcacy of an inﬂammatory clinical disease model.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Leg press1. Introduction
Resistance exercise is a key component of a comprehensive exercise
training program for both athletes and recreationally active individuals.
Although resistance exercise is an effective means to increase lean
muscle mass in the long-term, in the short-term, resultant exercise
induced muscle damage (EIMD) and soreness can limit performance
in subsequent training sessions or competitive events [10]. Also EIMD
models are relevant because they can be used to mimic what happens
with various clinical conditions. Generally, delayed onset muscle sore-
ness (DOMS) and inﬂammation peak between 1 and 2 days following
a resistance exercise session. Non-steroidal anti-inﬂammatory drugs
(NSAIDs) are commonly used to treat DOMS [17]. While the reduction
of some inﬂammation may be therapeutic, the severe blunting of
inﬂammation caused by NSAID blocks or impairs the initial stage ofs, Dept. of Kinesiology, Health
g, Room 209, 1921 Chestnut
. This is an open access article underhealing. Despite the perceived beneﬁts of NSAID, clinical research
demonstrates that NSAID use does not necessarily improve recovery
following EIMD [20]. Moreover, in some users, regular NSAID use has
been reported to exert negative effects on the central nervous system
[1]. Thus, investigating less damaging, naturally occurring, substances
that have anti-inﬂammatory actions is warranted.
While many different substances have been studied as a treatment
for EIMD and DOMS, curcumin is of special interest because it is pur-
ported to act through a similar mechanism as NSAID, albeit with a less
pronounced suppression of inﬂammation [24]. As such, curcumin acts
by modifying COX-2 pathway signaling, which results in reduced
inﬂammatory cytokine (i.e. IL-1β, IL-6, IL-8, and/or TNF-α) and prosta-
glandin production [9,13]. This modulation could be important since
prostaglandins play a role in increasing the severity of subjective pain
following EIMD and IL-8/TNF-α have emerged as stable blood
biomarkers of inﬂammation [2,18,22]. The known ability of curcumin
to reduce in vitro COX-2 signaling makes it an ideal candidate to treat
EIMD and DOMS; however, only a handful of studies have examined
this effect [6,7,12,14,19,21,23]. Of these published studies, two havethe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Subject characteristics.
Characteristic Curcumin (n = 16) Placebo (n = 12)
Gender (# F) 11 7
Age (y) 20 ± 1 19 ± 2
Height (M) 1.66 ± 0.09 1.70 ± 0.08
Weight (kg) 62.4 ± 11.4 65.0 ± 10.3
BMI 22.7 ± 3.5 22.3 ± 1.9
Body fat (%) 24.7 ± 9.4 23.3 ± 12.1
Muscle strength (1RM) 145 ± 42 202 ± 67
Total load lifted during EIMD (kg) 8972 ± 2670 12537 ± 4171
Values represent the mean ± SD.
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human studies either did not use a pure eccentric EIMDmodel (i.e. they
used downhill running or strenuous endurance exercise) [7,14,19,21,
23] or they used an impractical dose of naturally occurring curcumin
[19]. Another potential limitation with oral curcumin supplementation
is that not all curcumin supplements deliver free curcumin into the
blood [9]. Those that don't deliver free curcumin, deliver curcumin
metabolites that have a short half-life, are not readily absorbed by target
tissues, and have low bioactivity [9]. Given the limited number of previ-
ous publications there is clearly a need to complete additional research
to characterize the potential of curcumin supplementation to treat
EIMD and DOMS.
Another important factor to consider in the evaluation of previous
studies involving curcumin is the formof curcumin used. In its naturally
occurring state, curcumin has very low bioavailability in humans [3]
and, therefore, doses from murine models do not scale to reasonable
doses in humans [6,12]. For example, when considering a study
conducted by Davis et al. [6], a comparable dose in humans would
need to include at least 5 g/day of oral curcumin ingestion (~25,
400 mg capsules), which is not practical. With, a 5 g dose of naturally
occurring curcumin, the amount of bioactive curcumin present in the
blood would likely be less than 200 mg/day (b5% bioavailability of
naturally occurring curcumin) [9]. Recently, various forms of curcumin
that are “optimized” to address low bioavailability issues have become
commercially available [9].
The present study sought to expand the existing literature by de-
signing a study that ﬁrst identiﬁed an optimal dose of commercially
available, “optimized” curcumin needed to elicit a speciﬁc biological
effect (i.e. reduced serum TNF-α). We did not focus on measurements
of COX-2 or prostaglandins because the relationship of these outcomes
to curcumin supplementation is established. This optimal dosewas then
used to evaluate the efﬁcacy of curcumin as a treatment formuscle sore-
ness and biological inﬂammation following EIMD. Beyond implications
for EIMD, the ﬁndings of the present study have implications for clinical
conditions where chronic muscle damage occurs. The purpose of this
study was to determine the effects of oral curcumin supplementation
(400mg/day) on subjective quadricepsmuscle soreness, serumcreatine
kinase (CK), and serum inﬂammatory cytokines following 60 repeti-
tions of eccentric-only dual-leg press exercise at 110% of the 1RM.
2. Materials and methods
2.1. Ethical approval
The Institutional ReviewBoard (IRB) of theUniversity of North Texas
approved all procedures described in this report. All subjects provided
their verbal and written consent prior to participating in the study. All
procedures were completed according to the standards set by the latest
revision of the Declaration of Helsinki.
2.2. Design and determination of dosing
Prior to performing the present study, we completed a pilot experi-
ment (N = 20 subjects) to compare the effect of three oral doses of
curcumin (Longvida®; 200, 400, and 1000 mg) against a placebo to
identify an optimal dose needed to lower serum inﬂammatory
cytokines (data not shown). A pilot dose experiment was warranted
because doses used in murine model studies do not translate well to
human models and, to our knowledge, no existing human studies
have provided consistent information identifying an optimal dose to
alter serum inﬂammatory cytokines following EIMD. In this pilot
study, we found that a curcumin dose of 400 mg/day resulted in at
least a 19% blunting of serum TNF-α at either 1 or 2 days following
EIMD compared to placebo (effect size = 0.42). TNF-α blunting with
the 200mg/day dosewas substantially less (6%) with a very small effect
size (0.20). The 1000 mg/day dose did not result in a signiﬁcantly greatblunting of TNF-α than the 400 mg/day dose (minimum detection was
17%; effect size = 0.44 compared to placebo). Therefore, a dose of
400 mg/day was selected for the current study design. This study was
powered based on changes in serum TNF-α, which in our pilot experi-
ment had the smallest effect size and has been reported to change con-
sistently following EIMD [11]. By powering the study on the ability of
curcumin to blunt changes in serumTNF-α, it was calculated that amin-
imum of 12 subjects per group was needed (total N = 40). In order to
account for anticipated subject attrition/non-compliance (determined
to be 45% in our pilot experiment), we enrolled 20 subjects per group.
Subject attrition/non-compliance was broadly deﬁned to include sub-
jects that did not adhere to the study protocol (i.e. missed supplement
doses, missed study appointments, did not report to the lab fasted,
etc.), those that we could not collect a blood sample on due to dehydra-
tion or vascular anatomy, and subjects who asked to drop. In the case of
the present study, no subjects asked to drop, thus the key source of
attrition was associated with lack of adherence to the study protocol
or sample collection.2.3. Study population
Interested subjects were recruited from the campus by announce-
ments and word of mouth. Exclusion criteria included: regular resis-
tance training in the previous 6 months, leg muscle or orthopedic
condition, arthritis or other chronic inﬂammatory injury in the lower
extremity, regular ingestion (N2 times per week) of curcumin contain-
ing foods, regular NSAID use (at least 3 of 7 days), intake of a curcumin
supplement (within the past 6 months), and any other condition that
would prohibit completion of the lower body resistance exercise proto-
col. We experienced 30% attrition/non-compliance (as deﬁned above)
in the current study and 28 subjects completed the entire protocol
(Table 1).2.4. Muscle strength testing and familiarization
Approximately 10 days prior to themuscle damage session, subjects
were scheduled to report to the laboratory to complete a muscle
strength test. After being provided 5 min of dynamic warm-up on a
cycle ergometer, a light resistance (based on gender, age, and body
weight) was loaded onto a 45° inclined seated dual leg press and sub-
jects were familiarized with the exercise movement. Targeted cadence
for the repetitions (4 s concentric and 5 s eccentric) was maintained
using a metronome. After demonstration, the resistance was increased
and subjects were asked to complete as many repetitions as possible
using the prescribed cadence. The number of repetitions was recorded
and the 1 repetition maximum (1RM) was estimated using a standard
method [15]. The subject was scheduled to report back to the laboratory
2 days after the initial testing session to repeat the strength test. The
second 1RM estimate was used for the calculation of workloads for
the muscle damage protocol. The interclass coefﬁcient between the
1st and 2nd 1RM strength tests was N95%.
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Stratiﬁed randomization (based on gender and initial strength) was
used to assign subjects to the treatment conditions to ensure similar
numbers of men and women and a balance based on initial muscle
strength between conditions. Commercially available curcumin supple-
ments were used for the present study (Longvida®; Verdure Sciences
Corp.; Noblesville, IN). Subjects were provided supplements using a
double-blind approach beginning 2 days prior to EIMD and continuing
until 3 days after EIMD. Subjects consumed either 400 mg of rice ﬂour
(placebo) or curcumin daily (total study dose = 2400 mg) depending
on the condition they were assigned to. Capsules were ingested after
rising in the morning and following an overnight fast (N8 h). Subjects
reported no adverse gastrointestinal effects. With the exception of the
2 days prior to EIMD, subjects took their recovery supplements (PRE,
1, 2, 3, and 4 dayspost-EIMD) in the presence of a member of the
study staff. During the 2 days prior to EIMD, subjects conﬁrmed supple-
mentation ingestion via a text message to the study staff. Subject
compliance during this phasewas 100% for the subjects who completed
all study requirements. Subjects who failed to take the supplement as
prescribed were dismissed from the study and their samples were not
analyzed.
2.6. Exercise-Induced Muscle Damage (EIMD) protocol
Subjects completed 6 sets of 10 repetitions of the leg press exercise
with a beginning load set at 110% of their estimated 1RM. As in the fa-
miliarization sessions, subjects were asked to maintain a 5-s eccentric
contraction on the leg press, with the assistance of a metronome. The
5-s eccentric phase was selected to maximize the duration of eccentric
contraction and thus EIMD [25]. Two spotters assisted the subjects dur-
ing the concentric phase of contraction to reducemuscle fatigue. During
subsequent sets, if a subject was unable to maintain the 5-s eccentric
contraction duration the resistance was reduced by 2.2 kg for that set
and subsequent sets. Every precaution was taken to carefully adjust
leg press resistance so that the subject could maintain the prescribed
speed of eccentric contraction. Sets were separated by 5 min of passive,
seated rest.
2.7. Subjective quadriceps muscle soreness
The dual leg press exercise involved several different lower extrem-
ity muscle groups, and we made our measures of soreness on the
anterior thigh (i.e. quadriceps) and used those as representative of the
other muscles in the leg. Subjective quadriceps muscle soreness was
measured at three anatomical locations (distal, middle, and proximal)
using an existing method [16,25]. Brieﬂy, a standard force (consistent
within subject, 20–30 N) was applied using a force gauge over the
targeted anatomical site in the seated position with the knee fully
extended and relaxed. Subjects were provided a 10 cm line with no
visual markers other than “anchors” at each end and asked to indicate
their level of soreness by crossing the line at a point they felt
corresponded to their soreness. In order to determine soreness score,
the same researcher “scored” each rating scale using a ruler by measur-
ing the distance from the left side “anchor” to the location the subject
“crossed.” The three ratings for each quadriceps were summated to
determine total quadriceps soreness scores for the right and left legs.
2.8. Activities of daily living (ADL) soreness
In addition to measuring subjective, palpated quadriceps soreness,
we also assessed the subject's soreness during completion of common
activities of daily living (ADL). To accomplish this, we used a modiﬁed
version of the Knee injury andOsteoarthritis Outcome Score (KOOS) de-
signed to ask aboutmuscle and joint soreness and its impact of activities
of daily living during the previous 1-day period. Values expressed arearbitrary units with higher scores representing greater levels of sore-
ness while completing ADLs.
2.9. Blood sample collection
Venous blood samples were collected prior to (PRE), 1, 2, 3, and
4 dayspost-muscle damage using standard phlebotomy technique
from an antecubital vein. Blood was collected into a serum separator
tube and allowed to clot. Once clotted, the blood was centrifuged
(1500 ×g for 20 min). Isolated serum was either analyzed for creatine
kinase concentration or frozen at−80 °C until cytokine analysis.
2.9.1. Measurement of serum creatine kinase
Creatine kinase (CK)wasmeasured in triplicate using a commercial-
ly available enzymatic assay (Pointe Scientiﬁc; Canton, MI) on an auto-
mated chemistry analyzer (ChemWell-T; Awareness Technologies;
Palm City, FL). Interassay CV was b8%.
2.9.2. Measurement of serum cytokines
Serum concentrations of IL-6, IL-8, IL-10, and TNF-αwere measured
according to our previously described multiplex technique [17]. Brieﬂy,
aliquots of serum were analyzed in duplicate using a high-sensitivity
bead-based multiplex assay, according to the manufacturer's recom-
mendations (Milliplex; EMD Millipore; St. Louis, MO). Acquired raw
data ﬁles were used to determine unknown concentrations using
Milliplex Analyst Software (EMD Millipore). Interassay CV was b9%.
2.10. Statistical analysis
Prior to formal statistical testing, data were checked for normality
and constant error variance. Data found to be in violation of these
assumptions were normalized using a log-transformation. Data were
statistically analyzed for signiﬁcance using a 2 (Group: curcumin or pla-
cebo) by 5 (time: PRE, 1, 2, 3, and 4 dayspost-muscle damage) analysis
of variance (ANOVA) with repeated measures on the second factor
(time). Signiﬁcance was set to P b 0.05 and signiﬁcant alpha values
were adjusted using theHuynh–Feldtmethod to account for the repeat-
ed measures design. Location of signiﬁcance effects was determined
using individual t-tests with a Bonferroni correction for multiple com-
parisons. All data are reported as the mean ± SE unless otherwise
indicated.
2.11. Heat map multivariate data visualization
One challenge associatedwithworkingwithmultivariate data sets is
that it can be difﬁcult to visualize global changes with all outcome var-
iables. This potential point of confusion was addressed by generating
heatmap plots to visualize all biomarker changes as a function of condi-
tion and measurement time (Fig. 4). We used a color scheme where
dark green represented the smallest response and dark red represented
the largest responsewithin a given outcome variable. Any response that
fell between small and large was shaded an intermediate color ranging
between green and red (see scale bar in Fig. 4). Responses were color
coded across outcome variable (i.e. CK, TNF-α, etc.) regardless of condi-
tion (i.e. placebo vs. curcumin).
3. Results
3.1. Subjective quadriceps muscle soreness
There was a signiﬁcant main effect for time associated with subjec-
tive muscle soreness for left quad (Fig. 1A; P = 0.001), right quad
(Fig. 1B; P = 0.002), and combined quad (Fig. 1C; P = 010). Peak mus-
cle soreness was observed at 2 days after EIMD regardless of how the
soreness was combined. There was no signiﬁcant difference in muscle
soreness between supplement conditions over time.
Fig. 1. Subjective quadricepsmuscle and ADL sorenesswas consistently used to assess perceivedmuscle soreness using a visual analog scale.Measurementsweremade prior to (PRE), 1, 2,
3, and 4 days following EIMD (Exercise-InducedMuscle Damage; 60 reps at 110% of the 1RM, eccentric only). Black bars represent placebo and gray bars represent curcumin. Summated
right (A), left (B), and combined (C) quadriceps sorenesswas assessed. Also ADL soreness (D)was assessed using a standard scale. † indicated legwith a signiﬁcant (P b 0.05) increase from
PRE across both groups at 1, 2, and 3 days following EMID. There was no signiﬁcant difference in muscle soreness between treatment conditions.
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There was a signiﬁcant main effect for time associated with ADL
soreness (Fig. 1D; P = 0.25). Peak ADL soreness scores were reached
at 2 days after EIMD and mirrored the changes observed in subjective
quadriceps muscle soreness. There was no signiﬁcant difference in
ADL soreness between supplement conditions over time.3.3. Serum creatine kinase
There was a signiﬁcant interaction (Fig. 2; P = 0.035) where
curcumin resulted in a blunted CK response at 1 day (−44%), 2 days
(−49%), 3 days (−57%), and 4 days (−69%) following EIMD compared
to placebo. Both conditions experienced a signiﬁcant increase in CK
following EIMD; however, the curcumin group had a signiﬁcantlyFig. 2. Serum creatine kinase (CK) measured prior to (PRE), 1, 2, 3, and 4 days following
EIMD (Exercise-Induced Muscle Damage; 60 reps at 110% of the 1RM, eccentric only).
Black bars represent placebo and gray bars represent curcumin. * indicated a difference
between curcumin and placebo groups (P b 0.05).smaller, blunted increase in CK that returned to baseline values
at 2 dayspost-damage. The placebo group on the other hand had a
much larger 1 day peak in CK and a second peak that occurred at
4 dayspost-damage.
3.4. Serum cytokines
Signiﬁcant interaction effects for curcumin supplementation were
found for both IL-8 (Fig. 3A; P = 0.030) and TNF-α (Fig. 3B; P =
0.028); however, changes in IL-6 (Fig. 3C) and IL-10 (Fig. 3D) did not
reach statistical signiﬁcance for this sample size. IL-8 was signiﬁcantly
lower with curcumin at 1 day (−21%) and 2 days (−18%) compared
to placebo. TNF-α was signiﬁcantly lower with curcumin at 1 day
(−25%), 2 days (−23%), and 4 days (−23%) compared to placebo.
TNF-α also trended toward being lower with curcumin at 3 days
(−19%). Despite the lack of signiﬁcance for IL-6, it did appear to demon-
strate a response similar to that of IL-8 and TNF-α (Fig. 3).
4. Discussion
The key ﬁnding was that oral curcumin supplementation
(400 mg/day) signiﬁcantly blunted serum creatine kinase, IL-8, and
TNF-α concentrations during recovery from EIMD. Despite reduced
biological indices of inﬂammation, we found no signiﬁcant reduction in
subjective quadriceps muscle soreness or ADL soreness with curcumin
compared to placebo for the current sample size. This ﬁnding was some-
what expected because we powered our study to detect changes in TNF-
α, but not necessarily changes in muscle soreness. Given the nature of
subjective muscle soreness measures and perceived soreness during
ADL, thesemeasures tend to have a lower effect size thanmore stable bi-
ological measures. Our ﬁndings agree in some ways (reduced CK and in-
ﬂammatory cytokines), but disagree in other ways (no reduction in
muscle soreness) with previously published reports involving curcumin
and EIMD [6,7,19,21,23]. Based on what is known about oral curcumin
supplementation in humans, it is plausible that this may be the primary
Fig. 3. Serum cytokines (IL-8 (A), TNF-α (B), IL-6 (C), and IL-10 (D)) measured prior to (PRE), 1, 2, 3, and 4 days following EIMD (Exercise-InducedMuscle Damage; 60 reps at 110% of the
1RM, eccentric only). Black bars represent placebo and gray bars represent curcumin. * indicated a signiﬁcant difference between curcumin and placebo groups (P b 0.05).
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curcumin to modulate recovery from EIMD is still an emerging ﬁeld of
study, the studies that have usednaturally occurring curcumin in humans
report either none or few biological effects, despite very high doses used
[19,21]. Nicol et al. [19] used amurine study [6] to select a human dose of
5000 mg/day of naturally occurring curcumin, which likely resulted in a
dose of b5% of bioavailable curcumin (b200 mg/day of bioactive
curcumin) being administered [9]. Consequently, Nicol et al. [19] report-
ed no alterations in biological indices of EIMD and only improvements in
subjective muscle soreness. In our pilot dosing experiment (data not
shown), we determined that a bioactive dose of at least 400 mg/day
wasneeded to alter biological indices of inﬂammation. Thus, the naturally
occurring dose used in the study by Nicol et al. [19] likely did not supply
enough free curcumin to elicit changes in inﬂammation biomarkers.
Interestingly, they reported reduced subjective muscle soreness with
curcumin.Ourﬁndingswere exactly the opposite in thatweobserved im-
provements in biomarkers of inﬂammation, but these did not translate
into reduced quadriceps muscle soreness with curcumin. Given the
mechanism of action of curcumin (i.e. COX-2 signaling), it is difﬁcult to
explain how it would be possible to reduce soreness independent of
changes in inﬂammatory cytokines. Inﬂammation on the other hand is
regulated by a variety of pathways, so it is plausible that curcumin
exerted an independent effect on inﬂammation because it was acting
through one of those pathways.
Our key biological outcome was that curcumin supplementation re-
duced serum IL-8, TNF-α, and CK following EIMD. In our study curcumin
supplementation appeared to cause time differences in TNF-α
(suppression maintained for up to 4 days) and IL-8 (suppression main-
tained for up to 2 days) response. Both of these cytokines are pro-
inﬂammatory and thus the reduction we observed was consistent
with a curcumin-induced reduction in secondary chemical damage to
the muscle, which is the primary cause of the biphasic DOMS response
[5,25]. Our ﬁndings with respect to pro-inﬂammatory cytokines are
consistent with reports in mice [6,12], albeit with a lower daily dose of
curcumin. In humans, Drobnic et al. [7] reported that anothercommercially available form of curcumin (400 mg/day) reduced IL-8
at 2 h after downhill running.When comparing peak CK concentrations
between the present study (Peak = 400 U/mL) and that of Drobnic
(Peak N 750 U/mL), it is reasonable to speculate that our measured
reduction in IL-8 at 1 day may correspond with the Drobnic reduction
reported at 2 h. Also, downhill running induces a more rapid muscle
damage curve (as measured by serum CK) due to oxidative stress creat-
ed by the highermuscle oxygen consumption of running [7,23]. Our ob-
served CK reduction with curcumin was consistent with what others
have reported using a variety of EIMD models [7,23]. Our time course
of CK response following EIMD did differ from other studies, but this
can be explained by comparing differences in the quantity of muscle
damage caused during the EIMD session [11]. As mentioned, the
amount of damage caused in the present study was much less than
that in the study by Drobnic et al. (downhill running), but more than
in the study by Nicol et al. (single leg eccentric contractions).
The ability of curcumin to alter inﬂammation has been fairly consis-
tently reported; however, measurement of perceived muscle soreness
and ADL soreness has yielded inconsistent reports [7,14,19,21,23].
Based on previous mechanistic work [4,13], the assumption would be
that muscle soreness reduction was a result of altered prostaglandins
from decreased COX-2 signaling, which should also decrease inﬂamma-
tory cytokines. In addition to potential differences in signaling path-
ways, muscle soreness can be inﬂuenced by an individual's perception
[8]. In contrast, decreased inﬂammatory cytokines is a physiological
process with no apparent psychological component in the context of
EIMD. The ﬁndings from other investigators that curcumin reduced
muscle soreness independent of reduced inﬂammation support the hy-
potheses that either different signaling pathways are involved or there
is an unaccounted for psychological component related to curcumin in-
gestion [19,21]. It should be noted that in the literature there are dozens
of accepted ways to measure muscle soreness. In the current study we
used an investigator-initiated measure of muscle soreness; however, it
is possible that had we used a different technique, we may have found
a different response. Method differences aside, it is also plausible that
Fig. 4. Heat map for global changes. A standard heat map was generated using a green
(smallest response) to red (largest response) color scale to graphically represent each
biomarker change (i.e. CK, TNF-α, etc.) as a function of treatment condition (curcumin
vs. placebo). The included scale demonstrates the full range of responses. Measurements
were made prior to (PRE), 1, 2, 3, and 4 days following EIMD (Exercise-Induced Muscle
Damage; 60 reps at 110% of the 1RM, eccentric only). This ﬁgure demonstrates that
curcumin treatment was associated with a muted response for serum cytokines (IL-6,
IL-8, IL-10, and TNF-α) and creatine kinase (CK). Further interpretation reveals that
while not signiﬁcant at this sample size, the muscle soreness response for curcumin
treatment matches with the inﬂammation biomarkers, particularly at 1 and 2 days.
Globally this ﬁgure illustrates the close relationship between the biomarkers used in this
study to evaluate recovery following EIMD.
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attributed to placebo effect associated with curcumin supplementation.
From a practical perspective, muscle soreness does not necessarily im-
pact function. In contrast, muscle inﬂammation directly interferes
with muscle function (i.e. reduced range of motion, reduced contractile
ability, etc.). Thus, between these two outcomes, a curcumin-induced
reduction in inﬂammation represents a greater potential to allow for
more rapid muscle recovery.
One challenge of studies that involve multiple outcome variables is
that it can be complicated to integrate the ﬁndings to create a proﬁle
of the observed treatment response. We addressed this challenge by
using heatmap plotting of key outcome variables (Fig. 4). This approach
allowed us to present a curcumin response proﬁle following EIMD that
incorporated all of our key outcome variables. Based on the heat map it
appears that biomarkers of muscle damage (CK) and inﬂammatory
cytokines (IL-6, IL-8, and TNF-α) were blunted in a similar manner
compared to placebo. While we did not detect signiﬁcant treatment
differences for quadriceps muscle or ADL soreness, there does appear
to be slightly less soreness at 1 day with curcumin. Another interesting
observation is that by 4 days the curcumin supplemented group had
rectiﬁed muscle damage and inﬂammation, while these responses
were still elevated in placebo. Our observed curcumin response proﬁle
(i.e. blunted CK, IL-8, and TNF-α) was consistent with what has been
collectively reported in the scientiﬁc literature [6,7,14,19,21,23].
In summary, the novel ﬁnding of the present study was that oral
supplementation with “optimized” curcumin (400mg/day) was associ-
ated with a blunting of serum CK, IL-8, and TNF-α for up to 4 days
following EIMD. A major strength of the present study is that we had
completed a pilot experiment to evaluate curcumin dose response,and we were able to properly power the present study to detect
curcumin-induced changes in markers of inﬂammation. It is plausible
to speculate that observed biological reductions may be due to
curcumin-induced reduction in secondary chemical injury to themuscle
during recovery. Unfortunately, the present study does not resolve
confusion regarding the ability of curcumin to reduce muscle soreness
following EIMD. While we carefully controlled all aspects of the study
and the measurements made, no experimental study is without limita-
tions; however, we believe that the strength of the ﬁndings outweighs
any of our shortcomings. Future research should seek to systematically
examine the nature of the relationship between oral curcumin dose,
blood curcumin concentration (via LC–MS), blood inﬂammatory
cytokines, and the EIMD/DOMS time course.Transparency document
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